Windgap Medical Closes Over $39M Series B-1 Funding

images 1

Windgap Medical, a Watertown MA-based provider of pharmaceutical and drug delivery systems, has raised $39M through Series B-1 funding.

Taiwania Capital led the round with participation by Shepherd Kaplan Krochuk and Molex Ventures.

The company plans to use the funds for epinephrine marketing and to expand the product pipeline that uses autoinjector technology.

Windgap, led by Christopher Stepanian (CEO) and Brent Buchine Ph.D. (CTO), is a pharmaceutical company that focuses on patient solutions using its patented dry/wet drug delivery platforms. This platform will soon be used to produce epinephrine, which is used for anaphylaxis. Another pipeline product is epinephrine for the treatment of anaphylaxis, which is sponsored by the National Institutes of Health via a multiyear CounterACT grant. It was developed by the University of Minnesota Twin Cities.

The FDA has not reviewed Windgap products, but the company plans to apply for approval for its epinephrine drug for anaphylaxis.

Get latest news from African Startup ecosystem

Latest stories

You might also like...